Locoregional Treatment for De Novo Metastatic
Nasopharyngeal Carcinoma

TORAMAN, Kübra ÖZKAYA; altun, musa; DİZDAR, Yavuz

doi:10.5505/tjo.2020.2623

Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma

Yavuz DİZDAR, (İstanbul Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, İstanbul, Türkiye)

Kübra ÖZKAYA TORAMAN, (İstanbul Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, İstanbul, Türkiye)

Musa ALTUN (İstanbul Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, İstanbul, Türkiye)

Türk Onkoloji Dergisi

4 4

Yıl: 2021 Cilt: 36 Sayı: 2 Sayfa Aralığı: 177 - 183 Metin Dili: Türkçe DOI: 10.5505/tjo.2020.2623 İndeks Tarihi: 04-06-2022

Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma

Öz:

Optimal management of de novo metastatic nasopharyngeal carcinoma (NPC) is debatable. The aim of this study is to evaluate the patient characteristics, the impact of locoregional treatment on disease control and overall survival (OS) and to analyze the factors that correlate with the outcome of patients with de novo metastatic NPC patients treated between 2000 and 2018. METHODS Among 589 NPC patients referred to our clinic in the past 18 years, the cases of 36 de novo metastatic NPC patients who received radical locoregional radiotherapy (LR-RT) were analyzed retrospectively. After excluding one patient who had previously received chemotherapy for 12 courses in another clinic, the remaining 35 patients were analyzed in terms of population characteristics, OS, and possible confounding factors. RESULTS Seven of 35 patients were under the age of 16. The histology was World Health Organization (WHO) type 2-3 in 94.3%. All but two patients received 3-6 cycles of induction chemotherapy. The median dose of LR RT was 70 Gy. The median follow-up time was 25 months. Two and 4 year OS rate was 51% and 34%, respectively. Univariate analysis showed no significant effects of age (>6, ≤40), gender, oligometastatic disease, the existence of liver metastasis, or RT dose on the OS. CONCLUSION De novo metastatic NPC patients had highly prolonged survival with the use of LR-RT and this treatment approach should be validated by further multi-centric clinical studies.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Lee A, Lin J, Ng W. Current management of nasopharyngeal cancer. Semin Radiat Oncol 2012;22(3):233– 44.
2. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994;21(3):382–97.
3. National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/ pdf/head-and-neck.pdf. Accessed Mar 10, 2021.
4. Chen WZ, Zhou DL, Luo KS. Long-term observation after radiotherapy for nasopharyngeal carcinoma (NPC). Int J Radiat Oncol Biol Phys 1989;16(2):311–4.
5. Frezza G, Barbieri E, Emiliani E, Silvano M, Babini L. Patterns of failure in nasopharyngeal cancer treated with megavoltage irradiation. Radiother Oncol 1986;5(4):287–94.
6. Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978;4(3–4):182–98.
7. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23(2):261–70.
8. Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, et al. Prospective study of tailoring whole-body dualmodality [18f] fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein- Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2013;31(23):2861–9.
9. Chan AT, Grégoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, et al; EHNS-ESMO-ESTRO Guidelines Working Group. Nasopharyngeal cancer: EHNS-ESMOESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii83–5.
10. Lang J, Hu C, Lu T, Pan J, Lin T. Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives. Cancer Manag Res 2019;11:6365–76.
11. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393(10185):2051–8.
12. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the “pre-metastatic niche”: within bone and beyond. Cancer Metastasis Rev 2006;25(4):521–9.
13. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour- mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8(12):1369–75.
14. Seisen T, Sun M, Leow JJ, Preston MA, Cole AP, Gelpi- Hammerschmidt F, et al. Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the national cancer data base. J Clin Oncol 2016;34(29):3529–36.
15. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–9.
16. Lin S, Tham IW, Pan J, Han L, Chen Q, Lu JJ. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. Am J Clin Oncol 2012;35(5):474–9.
17. Chen MY, Jiang R, Guo L, Zou X, Liu Q, Sun R, et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer 2013;32(11):604–13.
18. Rusthoven CG, Lanning RM, Jones BL, Amini A, Koshy M, Sher DJ, et al. Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol 2017;124(1):139–146.
19. Zou X, You R, Liu H, He YX, Xie GF, Xie ZH, et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer 2017;77:117–26.
20. You R, Liu YP, Huang PY, Zou X, Sun R, He YX, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol 2020;6(9):1345–52.
21. Chua ML, Ong SC, Wee JT, Ng DC, Gao F, Tan TW, et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck 2009;31(3):346–54.
22. Ng SH, Chan SC, Yen TC, Chang J, Liao CT, Ko SF, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 2009;36(1):12– 22.
23. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, et al. radical nephrectomy plus interferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966–70.
24. Gomez DR, Blumenschein GR Jr., Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17(12):1672–82.
25. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al; evaluation of drug efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392(10162):2353–66.
26. Kumar A, Kumar H, Dhanushkodi M, Ganesharajah S. Metastatic nasopharyngeal carcinoma: outcome from Cancer Institute, Chennai. Indian J Med Paediatr Oncol 2020;41:198–201.
27. Sun XS, Liang YJ, Liu SL, Li XY, Chen QY, Guo SS, et al. Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma. Oral Oncol 2019;94:73–9.
28. Riaz N, Sherman E, Lee N. The importance of locoregional therapy in metastatic nasopharyngeal cancer. JAMA Oncol 2020;6(9):1353–4.

APA	DİZDAR Y, TORAMAN K, altun m (2021). Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. , 177 - 183. 10.5505/tjo.2020.2623
Chicago	DİZDAR Yavuz,TORAMAN Kübra ÖZKAYA,altun musa Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. (2021): 177 - 183. 10.5505/tjo.2020.2623
MLA	DİZDAR Yavuz,TORAMAN Kübra ÖZKAYA,altun musa Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. , 2021, ss.177 - 183. 10.5505/tjo.2020.2623
AMA	DİZDAR Y,TORAMAN K,altun m Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. . 2021; 177 - 183. 10.5505/tjo.2020.2623
Vancouver	DİZDAR Y,TORAMAN K,altun m Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. . 2021; 177 - 183. 10.5505/tjo.2020.2623
IEEE	DİZDAR Y,TORAMAN K,altun m "Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma." , ss.177 - 183, 2021. 10.5505/tjo.2020.2623
ISNAD	DİZDAR, Yavuz vd. "Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma". (2021), 177-183. https://doi.org/10.5505/tjo.2020.2623

APA	DİZDAR Y, TORAMAN K, altun m (2021). Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. Türk Onkoloji Dergisi, 36(2), 177 - 183. 10.5505/tjo.2020.2623
Chicago	DİZDAR Yavuz,TORAMAN Kübra ÖZKAYA,altun musa Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. Türk Onkoloji Dergisi 36, no.2 (2021): 177 - 183. 10.5505/tjo.2020.2623
MLA	DİZDAR Yavuz,TORAMAN Kübra ÖZKAYA,altun musa Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. Türk Onkoloji Dergisi, vol.36, no.2, 2021, ss.177 - 183. 10.5505/tjo.2020.2623
AMA	DİZDAR Y,TORAMAN K,altun m Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. Türk Onkoloji Dergisi. 2021; 36(2): 177 - 183. 10.5505/tjo.2020.2623
Vancouver	DİZDAR Y,TORAMAN K,altun m Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma. Türk Onkoloji Dergisi. 2021; 36(2): 177 - 183. 10.5505/tjo.2020.2623
IEEE	DİZDAR Y,TORAMAN K,altun m "Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma." Türk Onkoloji Dergisi, 36, ss.177 - 183, 2021. 10.5505/tjo.2020.2623
ISNAD	DİZDAR, Yavuz vd. "Locoregional Treatment for De Novo Metastatic Nasopharyngeal Carcinoma". Türk Onkoloji Dergisi 36/2 (2021), 177-183. https://doi.org/10.5505/tjo.2020.2623